Published in final edited form as:

Biochem Biophys Res Commun. 2012 August 03; 424(3): 624–628. doi:10.1016/j.bbrc.2012.07.007.

Ubiquitin Tagged Dominant Negative Induces Degradation of B-ZIP Proteins

Eric Rios-Doria¹, Raghunath Chatterjee¹, Jeffrey Zhao¹, Vikas Rishi¹, and Charles Vinson^{1,*}

¹Building 37, Room 3128, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA;

Abstract

B-ZIP transcription factors heterodimerize with dominant negative designs, termed A-ZIPs, in a dimerization specific manner and inhibit its ability to bind DNA. Different A-ZIPs produce unique phenotypes *in vivo* suggesting that they have distinct B-ZIP heterodimerization partners. However, the identification of the *in vivo* heterodimerization partners of different A-ZIPs remains problematic. To identify the *in vivo* heterodimerization partners, a chimeric protein containing two ubiquitin motifs at the N-terminal of the A-ZIP domain was designed. The presence of ubiquitin reduced the concentration of specific co-transfected B-ZIP proteins. The ubiquitin enhanced degradation of the B-ZIP heterodimeric partner is inhibited by the proteasome inhibitor MG-132. These ubiquitin tagged A-ZIP dominant negatives may be more active *in vivo* because their endogenous heterodimerization partners are degraded more efficiently. This may be a general strategy to identify protein interaction partners.

Keywords

B-ZIP domain; ubiquitin; trans; A-ZIP; dominant negative

1. INTRODUCTION

The 55 human B-ZIP proteins function as homodimers or heterodimers to bind DNA in a sequence-specific manner and regulate genes involved in cell growth and differentiation [1;2]. To understand the function of structurally related B-ZIP proteins, we have designed dominant negatives, termed A-ZIPs, which contain only the B-ZIP leucine zipper domain and an appended amphipathic α -helical sequence that replaces the B-ZIP basic region [3; 4; 5; 6; 7]. The A-ZIP proteins heterodimerize with B-ZIP proteins via their leucine zippers and the acidic extension forms a coiled-coil structure with the B-ZIP basic region, essentially zippers the leucine zipper into the basic region [2]. In our previous studies, we

*Address correspondence to: Charles Vinson, PhD; Building 37, Room 3128, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Tel: (301) 496-8753; Fax: (301) 496-8419; Vinsonc@mail.nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

have shown that the inhibition of B-ZIP DNA binding results in physiological effects in transgenic mouse models [8; 9; 10; 11].

Expression of the A-ZIP protein A-C/EBP in the epidermis of adult mice prevents skin papilloma formation. If A-C/EBP is expressed after papilloma formation, the papillomas regress [8]. In contrast, A-Fos expression in mammalian cells reduces Ha-*ras*-mediated cellular transformation [4] whereas A-Fos expression in mouse epidermis converts papillomas to benign sebaceous adenomas and prevents conversion into carcinomas [12]. A-CREB expression prevents papilloma formation but do not cause regression [9]. Taken together, these results suggest that the effective inhibition of B-ZIP DNA binding could be a clinically relevant molecular target.

We observe that the expression of the A-ZIP sometimes causes its *in vivo* B-ZIP target protein expression to be reduced [8] suggesting that the inhibition of B-ZIP DNA binding accelerates degradation. To enhance B-ZIP degradation, we appended two copies of ubiquitin to the A-ZIP. Ubiquitin is a 76-amino acid peptide that is covalently attached to proteins targeting them to the proteasome complex for degradation [13]. By tagging the A-ZIPs with ubiquitin, the B-ZIP/A-ZIP heterodimer may enter the ubiquitin proteasome pathway, leading to the degradation of the heterodimer [14; 15]. The induced rapid turnover of pathological B-ZIP proteins may transform ubiquitin-A-ZIPs into more potent dominant negatives.

2. Materials and Methods

2.1 B-ZIP, A-ZIP and Ubiquitin A-ZIP Plasmids

The B-ZIP domains of 10 different B-ZIP proteins (ATF2, C/EBP α , C/EBP β , CREB, cFos, FosB, cJun, JunB, JunD, VBP) containing a green fluorescent protein (GFP) tag were previously designed [16]. Additionally, the A-ZIP domain plasmids were constructed as described previously [17]. Three dominant negative designs (A-FOS, A-C/EBP α , A-CREB) containing plasmids were digested with HindIII and BamHI restriction enzymes. Ubiquitin protein domain was PCR amplified using primers containing HindIII or BamHI restriction enzyme sites and digested with HindIII and BamHI. Gel purified ubiquitin fragments were subsequently ligated into the HindIII-BamHI open site of pT5 plasmid. The resulting plasmid was DNA sequenced to ensure both the ubiquitin and A-ZIP design was present. After miniprep isolation and small-scale simplification, the ubiquitin-A-ZIP fragment was removed by its HindIII-NdeI sites and inserted into the complementary site on the CMV-500 vector; allowing for efficient cell transfections. The final construct was verified by digestion analysis with the HindIII and NdeI restriction enzymes. The protein sequence of ubiquitin-A-FOS is

MQIFVKTLTGKTITLEVESSDTIDNVKSKIQDKEGIPPDQQRLLIFAGKQLEDGRTLSDY
NIQKE
STLHLVLRRLRGGMQIFVKTLTGKTITLEVESSDTIDNVKSKIQDKEGIPPDQQRLLIFAG
KQL
EDGRTLSDYNIQKESTLHLVLRRLTGGPVATRDPDLQRAEELARENEELEKEAEEL
E QELAELEAETDQLEDEKSALQTEIANLLKEKEKL, (ubiquitin tags in italics and underlined, A-FOS in bold).

2.2 Cell Culture and Transfections

NIH3T3 (ATCC) cells were maintained in Dulbecco's Modified Eagle Medium with high glucose (Invitrogen), 10% bovine calf serum (Hyclone), and 1% Antibiotic/Antimycotic (Invitrogen) in a 5% CO₂ incubator at 37 °C. The cells were transfected with either GFP-tagged B-ZIP alone or co-transfected with A-ZIP or ubiquitin- A-ZIP. Transfections were carried out following standard protocol (Invitrogen); cells were plated at a density of 6×10^4 on 12-well cell culture clusters (Corning Incorporated) and were transiently transfected with a standardized total DNA plasmid amount (1.3 µg) and lipofectamine (4.0 µl per well) in serum-reduced OPTI-MEM media (Gibco-Invitrogen). After 4 hrs of transfection, OPTI-MEM media were replaced with serum rich media and cultured for 24 hrs. Cultures were checked for GFP expression with fluorescence microscopy and harvested 24 hrs post-transfection using RIPA buffer with a Protease Inhibitor Cocktail Tablet (complete-Mini EDTA-free, Roche). Subsequent BSA protein concentration assays were carried out using standard procedures (Thermo Scientific).

For proteasome inhibition assays, MG-132 (Sigma-Aldrich) was added to the cells at 0, 2.5, 5, and 10 µM concentrations [18]. The compound was suspended in DMSO and added to the cells 4 hours post-transfection in fresh media. Controls were kept in DMSO without inhibitor.

2.3 Western Blot Analysis

Pre-determined amounts of protein were denatured in 1x NuPAGE loading buffer (Invitrogen), 50mM DTT, and RIPA buffer-Protease inhibitor solution at 70°C for 10 minutes. Samples were loaded onto NuPAGE 4-12% Bis-Tris Gel (Invitrogen) and run for SDS electrophoresis (150V, 90min). Proteins were then transferred onto a polyvinylidene difluoride membrane (PVDF, Invitrogen) at 30V for 90 min. The membrane was incubated for 1 hr at room temperature in PBS-T (pH7.4, 1x PBS, 0.1% Tween20) containing 5% non-fat dry milk (American Bioanalytical), and then incubated overnight at 4°C with primary antibodies in milk solution. Antibodies were used for GFP (1:1000 dilution, sc-9996) and the Beta-Actin control (1:2000 dilution, sc-47778). Following the incubations, membranes were rinsed 3×10 min with PBS-T. Anti-Mouse IgG secondary antibody (1:5000 dilution, Amersham Biosciences) was suspended in the milk solution and subsequently added to the membrane. The incubation period was kept rocking at RT for 1 hr. Membranes were then washed another 3×10 min. Chemofluorescence was detected using the ECL Plus western blotting detection kit (Thermo Scientific).

2.4 Reverse transcriptase PCR (RT PCR)

To ensure the effects of the dominant negative was not affecting the transcriptional level, the RNA was analyzed for a two-step RT-PCR. RNA was isolated using TRIzol (Invitrogen) using standard protocol. The isolated product was treated with RNase-Free DNase I to digest the DNA impurities and subsequently inactivated by incubating at 65°C for 5 min. cDNAs were generated using cDNA preparation Kit (Promega) as suggested by the manufacturers protocol. PCR amplifications were performed with the 1 µl of cDNA template of the cJun/FOS system, 4 µl of PCR ReadyMix (Sigma-Aldrich), 3µL of PCR quality water and 1

μl each of forward and reverse primers. GFP primers, A-FOS primers, and GAPDH primers used are listed below.

GFP Primers:	Forward 5' GCACGACTTCTTCAAGTCCGCCATGCC 3'
	Reverse 5' GCGGATCTTGAAGTTCACCTTGATGCC 3'
A-FOS Primers:	Forward 5' CCGAAGAGCTGGAGCAGGAA 3'
	Reverse 5' TAATCAGGGATCTTGCAGGC 3'
GAPDH Primers:	Forward 5' ATGTTCCAGTATGACTCCACTCACG 3'
	Reverse 5' GAAGACACCACTAGACTCCACGACA 3'

The reaction conditions were: 1 hold for 9 min at 94°C; 35 cycles of 30 sec at 94°C, 30 sec at 62°C, and 30 sec at 72°C; 1 hold for 7 min at 72°C. The PCR product was visualized on a 2% agarose gel.

3. RESULTS

3.1 Expression of Ubiquitin tagged A-ZIPs

We evaluated if the addition of ubiquitin to the A-ZIP dominant negatives would cause their B-ZIP dimerization partner to be degraded more efficiently. We generated plasmids encoding chimeric proteins termed ubiquitin-A-ZIPs which contained two copies of the 76-a.a. yeast ubiquitin appended to the N-terminus of A-ZIPs (Figure 1). Three plasmids containing ubiquitin tagged A-ZIP dominant negatives were examined ubiquitin-A-C/EBP that heterodimerizes with C/EBP family members [2], ubiquitin-A-CREB that heterodimerizes with CREB family members [5], and ubiquitin-A-FOS that heterodimerizes with JUN family members [4].

Initially, we examined how different concentrations of A-ZIP and ubiquitin-A-ZIP would affect co-transfected GFP-B-ZIP protein concentrations. In the co-transfection experiments, the GFP-B-ZIP protein levels were monitored using a GFP antibody (Figures 2A-C).

Ubiquitin-A-C/EBP is more potent than A-C/EBP at diminishing GFP-C/EBPα protein concentrations (Figure 2A). A GFP-C/EBPα to ubiquitin-A-C/EBP plasmid ratio of 1:3 produced lower GFP-C/EBPα protein concentrations than a GFP-C/EBPα to A-C/EBP plasmid ratio of 1:3. When the ratio was 1:5, both dominant negatives produced low GFP-C/EBPα concentrations. Similarly, GFP-cJun proteins concentrations were lower when ubiquitin-A-FOS is used. Ubiquitin-A-CREB also showed some activity.

3.2 Addition of MG-132 Proteasome Inhibitor

We hypothesize that the reduction in B-ZIP protein concentration with the addition of ubiquitin to the A-ZIP is mediated through the proteasomal degradation pathway. To test this hypothesis, we inhibited the proteasome using the proteasome inhibitor MG-132 [18] and measured GFP-B-ZIP protein concentration. This inhibition prevented both ubiquitin-A-C/EBPα and ubiquitin-A-FOS to decrease their specific B-ZIP protein concentrations (Figure 2D). The proteasomal inhibitor increased both GFP-C/EBPα and GFP-cJun protein levels

even when no dominant negative is present. These data suggest that the ubiquitin is targeting the ubiquitin-A-ZIPB-ZIP heterodimer into the proteasome degradation pathway.

3.3 GFP-C/EBPα localization

GFP-C/EBPα cellular localization using fluorescence microscopy was determined when co-transfected in the 3T3 cell line either with A-C/EBP or ubiquitin-A-C/EBP. When GFP-C/EBPα was transfected alone it primarily localized in the nucleus and co-transfection with A-C/EBP changes the localization to the cytoplasm which is consistent with our previous observations (Figure S1) [16]. However, co-transfection with the ubiquitin tagged A-C/EBP drastically reduced the cytoplasmic localization of GFP-B-C/EBPα thus suggesting their degradation. Addition of the proteasome inhibitor, MG-132, again increases the cytoplasmic localization and supports our hypothesis that degradation of the A-ZIPB-ZIP complex is mediated through the proteasomal degradation pathway.

3.4 RT-PCR of MG-132 treated GFP-cJun/A-FOS

To evaluate if the dominant negatives are acting at a transcriptional level, the mRNA concentrations of the exogenous B-ZIPs were analyzed (Figure 3). A-FOS primers were designed to cover the leucine zipper as well as part of the acidic extension, so that it would not amplify the endogenous cFOS. The A-FOS primers on the cDNA amplify all the appropriate experimental samples along with control plasmids (Figure 3B). GFP and GAPDH primers were used as positive controls (Figure 3C-D). All samples have expected band except for the stock plasmids, which were not transfected into the cells. Figure 3E confirms that there was no DNA contamination present during the isolation of mRNA samples, only the A-FOS and ubiquitin-A-FOS plasmids produced the proper PCR products. These results confirm that the A-FOS and cJun expression seen on the western blot occurred is not at the transcriptional level.

3.5 Ubiquitin-A-ZIP Specificity to B-ZIPs

To evaluate the specificity of the ubiquitin tagged dominant negatives, three different ubiquitin tagged A-ZIPs were co-transfected with one of eleven GFP-B-ZIP encoding plasmids (Figure 4). The most drastic effect came with ubiquitin A-FOS specifically inhibiting protein concentrations of the three Jun family members examined (GFP-cJun, GFP-JunB, and GFP-JunD). Ubiquitin-A-C/EBPα produced a specific drop in GFP-C/EBPα protein. These results demonstrate the selective action of the ubiquitin-A-ZIP dominant negative constructs.

4. DISCUSSION

We have previously reported the inhibition of DNA binding of B-ZIP transcription factors using dominant negative proteins that interact with the DNA binding region of the B-ZIP domain [2; 3; 4; 5]. These A-ZIP dominant negative produce distinct phenotypes in transgenic mice and sometimes cause their target B-ZIP proteins to disappear [8; 9]. Two possible mechanisms are the A-ZIPB-ZIP heterodimer can not be retained in the nucleus because it does not bind to DNA, is shuttled to the cytoplasm where it is degraded or the A-ZIPB-ZIP heterodimer forms in the cytoplasm and can not be imported into the nucleus

because the nuclear localization signal, which is the basic region critical for sequence specific DNA binding [19], is sequestered in the coiled coil extension of the leucine zipper. Independent of the exact mechanism that cause the B-ZIP proteins to disappear when the A-ZIP is expressed [16], we added two copies of ubiquitin to enhance this process, exploring if ubiquitin could act in trans to degrade the B-ZIP protein in the ubiquitin-A-ZIP/B-ZIP heterodimer. This could both help identify endogenous B-ZIP targets and also increase the potency of the dominant negative. The approach is conceptually similar to siRNA technologies. The siRNA targets specific mRNAs for degradation, which can be monitored experimentally. Obtaining conceptually similar data for the A-ZIPs degradation of the B-ZIP heterodimeric partners would strengthen their utility in various experimental paradigms.

The transient transfections revealed several interesting phenomena. Expression of the A-FOS dominant negative induced co-transfected GFP-cJun protein concentrations by a mechanism that does not involve increased GFP-cJun mRNA. Neither GFP-C/EBP α nor GFP-CREB have this property when their A-ZIPs are expressed suggesting that it could be possible to map onto the A-FOS construct to explore which property causes GFP-cJun to increase in protein concentration.

GFP-B-ZIP protein concentration increased in the presence of the proteasome inhibitor MG-132 indicating that the proteasome is critical for regulating GFP-cJun protein. Both A-FOS and particularly ubiquitin-A-FOS can accelerate GFP-cJun degradation, again indicating that one can map onto A-FOS properties that are critical for the accelerated degradation. This may be a general strategy to identify complexes *in vivo*. A component of a complex can be tagged with ubiquitin and the concentration of other proteins could be monitored to reveal which proteins are in the complex.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Aaron Ciechanover for the twinkle in his eye when he heard about this idea and Stan Lipkowitz for insights about ubiquitin function.

Abbreviations:

B-ZIP domain	basic leucine zipper domain
CREB	CRE-binding protein
VBP	vitellogenin gene-binding protein
C/EBP	CAAT/enhancer binding protein
API	activator protein 1

References

- [1]. Hurst HC, Transcription factors 1: bZIP proteins. *Protein Profile* 2 (1995) 101–68. [PubMed: 7780801]
- [2]. Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, and Bonovich M, Classification of human B-ZIP proteins based on dimerization properties. *Mol Cell Biol* 22 (2002) 6321–35. [PubMed: 12192032]
- [3]. Krylov D, Olive M, and Vinson C, Extending dimerization interfaces: the bZIP basic region can form a coiled coil. *EMBO J* 14 (1995) 5329–37. [PubMed: 7489722]
- [4]. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, and Vinson C, A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. *J Biol Chem* 272 (1997) 18586–94. [PubMed: 9228025]
- [5]. Ahn S, Olive M, Aggarwal S, Krylov D, Ginty DD, and Vinson C, A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. *Mol Cell Biol* 18 (1998) 967–77. [PubMed: 9447994]
- [6]. Acharya A, Rishi V, Moll J, and Vinson C, Experimental identification of homodimerizing B-ZIP families in *Homo sapiens*. *J Struct Biol* 155 (2006) 130–9. [PubMed: 16725346]
- [7]. Zhang JW, Tang QQ, Vinson C, and Lane MD, Dominant-negative C/EBP disrupts mitotic clonal expansion and differentiation of 3T3-L1 preadipocytes. *Proc Natl Acad Sci U S A* 101 (2004) 43–7. [PubMed: 14688407]
- [8]. Oh WJ, Rishi V, Orosz A, Gerdes MJ, and Vinson C, Inhibition of CCAAT/enhancer binding protein family DNA binding in mouse epidermis prevents and regresses papillomas. *Cancer Res* 67 (2007) 1867–76. [PubMed: 17308129]
- [9]. Rozenberg J, Rishi V, Orosz A, Moitra J, Glick A, and Vinson C, Inhibition of CREB function in mouse epidermis reduces papilloma formation. *Mol Cancer Res* 7 (2009) 654–64. [PubMed: 19435810]
- [10]. Chatterjee R, Bhattacharya P, Gavrilova O, Glass K, Moitra J, Myakishev M, Pack S, Jou W, Feigenbaum L, Eckhaus M, and Vinson C, Suppression of the C/EBP family of transcription factors in adipose tissue causes lipodystrophy. *J Mol Endocrinol* 46 (2011) 175–92. [PubMed: 21321096]
- [11]. Jeong MY, Walker JS, Brown RD, Moore RL, Vinson CS, Colucci WS, and C.S. Long, AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation. *Am J Physiol Heart Circ Physiol* 298 (2010) H1719–26. [PubMed: 20363890]
- [12]. Gerdes MJ, Myakishev M, Frost NA, Rishi V, Moitra J, Acharya A, Levy MR, Park SW, Glick A, Yuspa SH, and Vinson C, Activator protein-1 activity regulates epithelial tumor cell identity. *Cancer Res* 66 (2006) 7578–88. [PubMed: 16885357]
- [13]. Liu YC, Penninger J, and Karin M, Immunity by ubiquitylation: a reversible process of modification. *Nat Rev Immunol* 5 (2005) 941–52. [PubMed: 16322747]
- [14]. Ciechanover A, Hod Y, and Hershko A, A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. *Biochem Biophys Res Commun* 81 (1978) 1100–5. [PubMed: 666810]
- [15]. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman, and Lipkowitz S, Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. *J Biol Chem* 276 (2001) 27677–84. [PubMed: 11375397]
- [16]. Heyerdahl SL, Rozenberg J, Jamtgaard L, Rishi V, Varticovski L, Akah K, Scudiero D, Shoemaker RH, Karpova TS, Day RN, McNally JG, and Vinson C, The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. *Eur J Cell Biol* 89 (2010) 564–73. [PubMed: 20362353]
- [17]. Krylov D, Echlin DR, Taparowsky EJ, and Vinson C, Design of dominant negatives to bHLHZip proteins that inhibit DNA binding. *Curr Top Microbiol Immunol* 224 (1997) 169–77. [PubMed: 9308240]
- [18]. Mazroui R, Di Marco S, Kaufman RJ, and Gallouzi IE, Inhibition of the ubiquitin-proteasome system induces stress granule formation. *Mol Biol Cell* 18 (2007) 2603–18. [PubMed: 17475769]

- [19]. Williams SC, Angerer ND, and Johnson PF, C/EBP proteins contain nuclear localization signals imbedded in their basic regions. *Gene Expr* 6 (1997) 371–85. [PubMed: 9495318]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Highlights:

- The dominant negative designs termed A-ZIPs heterodimerize with B-ZIPs.
- We designed a chimeric protein with two ubiquitin motifs at the N-terminal of A-ZIP.
- It results in degradation of B-ZIP heterodimerization partners more efficiently.
- This process of enhanced degradation is inhibited by proteasome inhibitor MG-132.

Figure 1. Schematic representation of A-ZIP dominant negative and Ubiquitin-A-ZIP,
A) Structure of B-ZIP domain (Fos|Jun heterodimer (1FOS)) in blue bound to DNA in red.
B) Coiled-coil heterodimer (359G) between a B-ZIP monomer (blue) and A-ZIP where the acidic extension is in red with two ubiquitin domains (in green).

Figure 2. GFP-B-ZIP chimeric proteins are degraded by Ubiquitin-A-ZIPs.

A) GFP-C/EBPα plasmid co-transfected with increasing equivalent concentrations of A-C/EBPα or ubiquitin-A-C/EBPα plasmid in NIH3T3 cells. **B)** GFP-cJun + A-FOS and GFP-cJun + ubiquitin-A-FOS **C)** GFP-CREB + A-CREB and GFP-CREB + ubiquitin-A-CREB **D)** GFP-ATF2 + A-ATF2 and GFP-ATF2 + ubiquitin-A-ATF2. The empty vector was added to all transfections to make DNA concentrations constant. In the western blot, antibodies were used either to GFP or to β-Actin. **D) MG-132 inhibits ubiquitin-A-ZIP degradation of B-ZIPs:** In the top panel, GFP-C/EBPα and A-C/EBPα or GFP-C/EBPα and ubiquitin-A-C/EBPα were co-transfected with increasing concentrations (0, 2.5, 5, 10 μM) of the proteasome inhibitor MG-132. Cells were harvested and western blots probed with antibody to GFP. In the bottom panel, co-transfected GFP-cJun and A-FOS or GFP-cJun and ubiquitin-A-FOS NIH3T3 cells were treated with MG-132. GFP antibodies were used for measuring the protein concentration of GFP-C/EBPα or GFP-cJun.

Figure 3. Protein and mRNA analysis of GFP-cJun cotransfected with A-FOS or ubiquitin-A-FOS.

A) GFP-cJun was co-transfected with A-FOS or ubiquitin-A-FOS and treated with increasing MG132 concentrations (0, 2.5, 5, 10 μ M) and visualized with a GFP antibody. **B)** PCR product using A-FOS primers with plasmids (lanes 1-2) or cDNA (lanes 3-14) used as template. **C)** PCR product using GFP primers and plasmids (lanes 1-2) or cDNA (lanes 3-14) used as template. **D)** PCR product using GAPDH primers with plasmids (lanes 1-2) or cDNA (lanes 3-14) used as template. **E)** PCR product using A-FOS primers with plasmids (lanes 1-2) or RNA (lanes 3-14) used as template. All PCR products produced the expected band size (A-FOS primers, 160-bp; GFP primers, 280-bp; GAPDH, 190-bp) when visualized on 2% agarose gel.

Figure 4. GFP B-ZIP proteins co-transfected with Ubiquitin-A-ZIP proteins.

A library of 11 GFP B-ZIP constructs (cJun, JunB, JunD, C/EBP α , C/EBP β , cFos, FosB, CREB, ATF-2, VBP, and LZ) were co-transfected with 2 A-ZIP constructs (A-FOS or A-C/EBP) with or without ubiquitin. GFP-B-ZIP protein concentration was monitored using a GFP antibody. The plasmid ratio between the GFP-B-ZIPs and A-ZIP or ubiquitin-A-ZIPs is 1:3.